Hob Biotech collaborates with Roche Diagnostics in the field of chemiluminescent autoantibody detection products
Hob Biotech and Roche Diagnostics signed a cooperation framework agreement, and both parties will collaborate in the field of chemiluminescent self-antibody testing products. This initiative aims to enhance Hob Biotech's brand recognition in the domestic market and expand its market share in the diagnostic reagent field. Although the agreement is a framework statement, specific cooperation projects need to be signed separately, and there is uncertainty in the implementation and advancement
According to the Zhitong Finance APP, Hob Biotech (688656.SH) announced that the company has signed a "Cooperation Framework Agreement" with Roche Diagnostics Products (Shanghai) Co., Ltd. (referred to as "Roche Diagnostics") to collaborate in the field of chemiluminescent autoantibody detection products.
The signing of this "Cooperation Framework Agreement" is an important measure to implement the company's long-term development strategy. The collaboration with Roche Diagnostics is beneficial for enhancing the company's brand recognition in the domestic market, further expanding the company's market share in the diagnostic reagent field, and has positive significance for the company's development. The company will communicate and learn from each other through this cooperation, continuously improving its own capabilities to provide customers with higher quality products and services.
The "Cooperation Framework Agreement" signed this time is a framework statement based on the intention of both parties to cooperate, does not constitute a mandatory legal obligation, nor does it serve as a basis for either party to pursue liability for breach of contract. Specific cooperation projects will require separate cooperation agreements, and there is a certain degree of uncertainty regarding whether the cooperation between the two parties can be implemented smoothly
